



## ASX ANNOUNCEMENT

### Release of Shares from Escrow

**MELBOURNE, Australia (11 February 2022):** Lumos Diagnostics (ASX: LDX) advises that, in accordance with ASX Listing Rule 3.10A and as stated in the Prospectus dated 7 June 2021 and the Pre-Quotation Disclosure dated 1 July 2021, 7,823,595 fully paid ordinary shares will be released from escrow at 4:15pm on the date on which the Company releases its preliminary results to ASX for the financial half year ending 31 December 2021 which is expected to occur by 28 February 2022.

These shares are already quoted on ASX.

This announcement has been authorised for release to the market by the Company Secretary.

###

#### About Lumos Diagnostics

Lumos Diagnostics specialises in rapid, cost-effective, and complete point-of-care (POC) diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customised assay development and manufacturing services for POC tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercialises novel Lumos-branded POC tests that target infectious and inflammatory diseases.

For more information visit [lumosdiagnostics.com](https://lumosdiagnostics.com) or call +1 941-556-1850.

#### Media Contact:

Matthew Wright – Australia  
Director, NWR Communications  
[matt@nwrcommunications.com.au](mailto:matt@nwrcommunications.com.au)  
+61 (0) 451 896 420

#### Investor Contact:

Matthijs Smith – Lumos Diagnostics  
[ir@lumosdiagnostics.com](mailto:ir@lumosdiagnostics.com)  
+61 411 137 080  
+61 3 9087 1598

#### Company Registered Office:

Lumos Diagnostics Holdings Ltd  
Level 4, 100 Albert Rd  
South Melbourne, VIC 3205  
+61 3 9087 1598